Scholarlink

<p>Therapeutic outcomes in solid tumors are shaped by drug potency and by heterogeneous tumor microenvironments that restrict vascular access, stromal penetration, local release, immune activation and durable response. Multifunctional nanotherapeutics have been developed to engage these barriers through pharmacokinetic optimization, vascular and stromal modulation, endogenous and exogenous stimuli-responsive release, immune-oriented intervention and imaging-guided treatment. However, the field remains challenged by heterogeneous human enhanced permeability and retention effects, uncertain translation of active targeting, context-dependent stromal biology, incomplete immune readouts and increasing chemistry-manufacturing-controls complexity as additional modules are integrated. This review organizes nanoplatforms through a tumor microenvironment phenotype-informed design logic that links biological barriers to design objectives, module choices, measurable readouts, evidence strength and translational constraints. Within this framework, we critically examine representative nanotherapeutic strategies across pharmacokinetic and biodistribution-oriented design, vascular and stromal normalization, tumor microenvironment-responsive activation, immune priming and intratumoral reprogramming, and clinically relevant theranostic approaches. We further discuss route of administration, patient stratification, safety, value assessment and rational platform simplification, emphasizing that future progress is more likely to depend on phenotype-matched and evidence-stratified deployment than on indiscriminate functional stacking.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multifunctional nanotherapeutics for tumor microenvironment modulation in solid tumor therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月25日

查看全文
  • Mengqi Yang,
  • Yedong Huang,
  • Weiye Qian,
  • Junye Zhu,
  • Liu Fei,
  • Zhixin Jiao,
  • Jian Wang,
  • Yifan Wang,
  • Wenbo Zhu,
  • Shun Chen,
  • Peipei Gong,
  • Ziheng Wang,
  • Zhichao Lu,
  • Rujun Liu,
  • Zhining Liu,
  • Qiaojun Hong,
  • Qingyu Luo,
  • Lin Zhang

摘要

Therapeutic outcomes in solid tumors are shaped by drug potency and by heterogeneous tumor microenvironments that restrict vascular access, stromal penetration, local release, immune activation and durable response. Multifunctional nanotherapeutics have been developed to engage these barriers through pharmacokinetic optimization, vascular and stromal modulation, endogenous and exogenous stimuli-responsive release, immune-oriented intervention and imaging-guided treatment. However, the field remains challenged by heterogeneous human enhanced permeability and retention effects, uncertain translation of active targeting, context-dependent stromal biology, incomplete immune readouts and increasing chemistry-manufacturing-controls complexity as additional modules are integrated. This review organizes nanoplatforms through a tumor microenvironment phenotype-informed design logic that links biological barriers to design objectives, module choices, measurable readouts, evidence strength and translational constraints. Within this framework, we critically examine representative nanotherapeutic strategies across pharmacokinetic and biodistribution-oriented design, vascular and stromal normalization, tumor microenvironment-responsive activation, immune priming and intratumoral reprogramming, and clinically relevant theranostic approaches. We further discuss route of administration, patient stratification, safety, value assessment and rational platform simplification, emphasizing that future progress is more likely to depend on phenotype-matched and evidence-stratified deployment than on indiscriminate functional stacking.